BeOne Medicines (BEIGF) Current Assets (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Current Assets data on file, last reported at $6.6 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $6.6 billion, up 69.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 billion (up 69.42% YoY), and the FY2025 annual result was $6.2 billion, up 56.17% from the prior year.
• Current Assets climbed to $6.6 billion in Q1 2026 per BEIGF's latest filing, from $6.2 billion in the prior quarter.
• Over five years, Current Assets peaked at $6.9 billion in Q1 2022 and troughed at $3.1 billion in Q4 2022.
• A 5-year average of $4.8 billion and a median of $4.3 billion in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2026: Current Assets tumbled 59.33% in 2022, then jumped 69.42% in 2026.
• A 5-year view of Current Assets shows it stood at $3.1 billion in 2022, then soared by 35.74% to $4.2 billion in 2023, then slipped by 5.04% to $4.0 billion in 2024, then jumped by 56.17% to $6.2 billion in 2025, then climbed by 5.9% to $6.6 billion in 2026.
• Business Quant data shows BEIGF's Current Assets at $6.6 billion in Q1 2026, $6.2 billion in Q4 2025, and $5.7 billion in Q3 2025.